Myriad Genetics (MYGN) – Bear of the Day
Source: http://www.zacks.com/commentary/12753/Myriad+Genetics+%28MYGN%29+-+Bear+of+the+DayPosted on Monday, November 16th, 2009 | In Investing Lessons, Stocks to Watch
Contributed by: Zacks Market Commentaries (http://www.zacks.com/) -
Myriad Genetics Inc. (MYGN) reported first quarter fiscal 2010 earnings of 31 cents per share, which was below the Zacks Consensus Estimate by a penny. The company had earned 25 cents per share in the year-ago period.
Myriad Genetics spun off its therapeutics business in July 2009 to focus on molecular diagnostics going forward. Although the molecular diagnostics business is performing well, we remain concerned about the slowdown in revenue growth in recent quarters.
The competition confronting Myriad Genetics products in the biotechnology and genetics testing field is also a concern. We have an Underperform rating on the stock.Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- Company News for February 9, 2010 - Corporate Summary - February 9th, 2010
- ADC Telecom Profit Tops - Analyst Blog - February 9th, 2010
- Stock Market News for February 9, 2010 - Market News - February 9th, 2010
- Nissan Results Improve - Analyst Blog - February 9th, 2010
- Nasdaq Beats on Low Charges - Analyst Blog - February 9th, 2010
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.